No connection

Search Results

AQST vs IVVD

AQST
Aquestive Therapeutics, Inc.
BEARISH
Price
$4.02
Market Cap
$490.5M
Sector
Healthcare
AI Confidence
85%
IVVD
Invivyd, Inc.
BEARISH
Price
$1.76
Market Cap
$497.7M
Sector
Healthcare
AI Confidence
90%

Valuation

P/E Ratio
AQST
--
IVVD
--
Forward P/E
AQST
-6.93
IVVD
-8.0
P/B Ratio
AQST
-14.57
IVVD
2.05
P/S Ratio
AQST
11.01
IVVD
9.31
EV/EBITDA
AQST
-5.84
IVVD
-4.98

Profitability

Gross Margin
AQST
58.34%
IVVD
92.99%
Operating Margin
AQST
-221.58%
IVVD
-72.96%
Profit Margin
AQST
-188.09%
IVVD
-98.25%
ROE
AQST
--
IVVD
-33.97%
ROA
AQST
-33.92%
IVVD
-17.09%

Growth

Revenue Growth
AQST
9.7%
IVVD
24.5%
Earnings Growth
AQST
--
IVVD
--

Financial Health

Debt/Equity
AQST
--
IVVD
0.01
Current Ratio
AQST
3.13
IVVD
7.24
Quick Ratio
AQST
2.92
IVVD
7.06

Dividends

Dividend Yield
AQST
--
IVVD
--
Payout Ratio
AQST
0.0%
IVVD
0.0%

AI Verdict

AQST BEARISH

AQST exhibits severe financial distress despite modest revenue growth, as evidenced by a Piotroski F-Score of 1/9—indicating weak operational and financial health. The company reports massive negative profitability metrics, including a -188.09% profit margin and -33.92% ROA, with no meaningful earnings or cash flow generation. Insider selling totaling $1.86M over six months, including significant sales by top executives, signals deep skepticism about future prospects. While the stock trades below its 52-week high and has a strong analyst consensus, the lack of intrinsic value support and deteriorating earnings trends undermine long-term viability. The absence of a valid Altman Z-Score and Graham Number further limits fundamental valuation reliability.

Strengths
Gross margin of 58.34% suggests strong pricing power or cost control in product manufacturing
Revenue growth of 9.70% YoY indicates some market traction despite losses
Current ratio of 3.13 and quick ratio of 2.92 reflect strong short-term liquidity
Risks
Piotroski F-Score of 1/9 signals extreme financial weakness and poor operational efficiency
Negative ROA (-33.92%) and ROE (N/A) indicate capital is not being deployed effectively
Insider selling by CEO, CFO, and COO totaling $1.86M in six months is a major red flag
IVVD BEARISH

Invivyd exhibits critical financial weakness, highlighted by a Piotroski F-Score of 0/9, indicating a complete lack of fundamental improvement across all measured categories. While the company maintains a strong liquidity position with a Current Ratio of 7.24 and very low debt, it is suffering from extreme operational inefficiency with a profit margin of -98.25%. There is a stark disconnect between the analyst 'Strong Buy' consensus (Target $10.00) and the deterministic data, which shows consistent earnings misses and bearish insider activity.

Strengths
High Gross Margin (92.99%) suggesting strong product pricing potential
Strong short-term liquidity with a Current Ratio of 7.24
Very low leverage with a Debt/Equity ratio of 0.01
Risks
Severe operational losses with a profit margin of -98.25%
Deterministic health failure (Piotroski F-Score 0/9)
Consistent failure to meet earnings estimates (1/4 beats in last 4 quarters)

Compare Another Pair

AQST vs IVVD: Head-to-Head Comparison

This page compares Aquestive Therapeutics, Inc. (AQST) and Invivyd, Inc. (IVVD) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.

Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.

Home
Terminal
AI
Markets
Profile